Blood and stool tests for colorectal cancer screening
Blood-based and multitarget stool tests for colorectal cancer screening.
Key point
Next-generation mt-sDNA and mt-sRNA are preferred 3-year stool options; blood-based tests should be recommended only when preferred screening tests are declined or incomplete.
From: Colorectal cancer screening: An update to the American Cancer Society guideline, 2026 (CA Cancer J Clin, 2026 May-Jun) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 18, 16, 16, 20, 20.
New guidelines and consensus this year
- Colorectal cancer screening: An update to the American Cancer Society guideline, 2026CA Cancer J Clin2026 May-Jun
All papers from the last 12 months
186 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Evaluating circulating tumor DNA methylation patterns of a multi-gene panel for colorectal cancer diagnosis: A pilot studyClin Chim Acta2027 Jan 1PMID 42320666
- Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling studyJ Med Econ2026 DecPMID 42339709
- Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopyJ Med Econ2026 DecPMID 41879223
- Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluationJ Med Econ2026 DecPMID 41764032
- Outcomes and Characteristics Across Age Groups of Patients with Positive MT-sDNA Stool Tests: Data from the New Hampshire Colonoscopy RegistryDig Dis Sci2026 NovPMID 42420696
- Cost-Effectiveness of Initiating Colorectal Cancer Screening at Age 40 Among Average-Risk Individuals in ChinaInt J Cancer2026 Oct 15PMID 42186152
- Return of Mailed Multitarget Stool DNA Test Kits and Subsequent Colorectal Cancer Incidence in the United States: A Retrospective Cohort StudyAdv Ther2026 Oct 11PMID 42859933
- An Artificial Intelligence-Based Blood Test using protein and miRNA biomarkers for Colorectal Cancer ScreeningClin Transl Gastroenterol2026 Oct 6PMID 42837662
- Rates of Aerodigestive Cancer After Positive mt-sDNA and Colonoscopy Without Advanced Colorectal Neoplasia in Patients with a Prior Cancer HistoryDig Dis Sci2026 Oct 6PMID 42836935
- Follow-up colonoscopy after abnormal stool-based colorectal cancer screening: a systematic review of completion, timeliness and implementation strategiesBMJ Open2026 Oct 5PMID 42833723Systematic review
More gastroenterology trends
All specialties →Third-space endoscopy
Peroral endoscopic myotomy and endoscopic submucosal dissection.
Potassium-competitive acid blockers
Vonoprazan and related acid suppressants.
AI in colonoscopy
Computer-aided polyp detection and characterisation during colonoscopy.
Metallic vs plastic biliary stents
Studies comparing metallic and plastic stents for biliary obstruction.
JAK inhibitors in IBD
Upadacitinib, tofacitinib and filgotinib in inflammatory bowel disease.
Key point: Tofacitinib and filgotinib are efficacious in ulcerative colitis, and upadacitinib is efficacious in both ulcerative colitis and Crohn’s disease.
Eosinophilic esophagitis
Diagnosis and newer treatments, including biologics, for eosinophilic esophagitis.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"colorectal cancer"[tiab] AND screening[tiab] AND ("blood-based"[tiab] OR "cell-free DNA"[tiab] OR cfDNA[tiab] OR "blood test"[tiab] OR "multitarget stool"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.